Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$49.33 USD
-1.57 (-3.08%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $49.50 +0.17 (0.34%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Corbus Pharmaceuticals Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 21 | 59 | 98 | 86 | 32 |
Receivables | 0 | 0 | 0 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 1 | 2 | 5 | 6 |
Total Current Assets | 24 | 60 | 100 | 92 | 38 |
Net Property & Equipment | 1 | 2 | 2 | 4 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 0 |
Total Assets | 28 | 66 | 108 | 102 | 49 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 2 | 2 | 7 | 11 |
Current Portion Long-Term Debt | 16 | 3 | 4 | 1 | 1 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 11 | 6 | 10 | 22 | 22 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 1 | 0 |
Total Current Liabilities | 32 | 13 | 17 | 32 | 35 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 16 | 16 | 18 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 35 | 33 | 39 | 57 | 43 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 430 | 425 | 419 | 349 | 199 |
Retained Earnings | -437 | -392 | -350 | -304 | -193 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -7 | 33 | 69 | 45 | 6 |
Total Liabilities & Shareholder's Equity | 28 | 66 | 108 | 102 | 49 |
Total Common Equity | -7 | 33 | 69 | 45 | 6 |
Shares Outstanding | 4.40 | 4.10 | 4.10 | 3.20 | 2.10 |
Book Value Per Share | -1.57 | 8.05 | 16.86 | 14.15 | 2.93 |
Fiscal Year End for Corbus Pharmaceuticals Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 147 | 120 | 21 | 29 | 37 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 2 | 2 | 2 |
Total Current Assets | 148 | 122 | 24 | 31 | 38 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 1 | 1 | 1 |
Total Assets | 152 | 126 | 28 | 36 | 44 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 2 | 3 | 5 | 2 |
Current Portion Long-Term Debt | 11 | 13 | 16 | 18 | 7 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 10 | 9 | 11 | 8 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 24 | 26 | 32 | 32 | 16 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 11 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 1 | 3 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 26 | 29 | 35 | 36 | 34 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 580 | 541 | 430 | 429 | 428 |
Retained Earnings | -454 | -444 | -437 | -429 | -419 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 126 | 97 | -7 | 0 | 10 |
Total Liabilities & Shareholder's Equity | 152 | 126 | 28 | 36 | 44 |
Total Common Equity | 126 | 97 | -7 | 0 | 10 |
Shares Outstanding | 10.60 | 10.50 | 4.40 | 4.40 | 4.40 |
Book Value Per Share | 11.84 | 9.24 | -1.57 | 0.07 | 2.16 |